Assembly Biosciences (ASMB) Operating Leases (2019 - 2026)
Assembly Biosciences (ASMB) posted quarterly Operating Leases of $1.9 million for Q1 2026, down 23.69% year-over-year from $2.5 million in Q1 2025, and down 7.67% quarter-over-quarter from $2.1 million in Q4 2025.
Assembly Biosciences (ASMB) Operating Leases (2019 - 2026) Analysis & Trends
Assembly Biosciences' Operating Leases history runs 8 years deep, the most recent figure standing at $1.9 million for Q1 2026.
- In Q1 2026, Operating Leases fell 23.69% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (down 23.69% YoY), while the FY2025 annual figure was $2.1 million, down 21.65% from the prior year.
- Operating Leases for Q1 2026 stood at $1.9 million, down from $2.1 million in the prior quarter.
- The five-year high for Operating Leases was $2.6 million in Q4 2024, with the low at $50000.0 in Q3 2023.
- The 5-year median for Operating Leases is $1.1 million (2023), against an average of $1.3 million.
- The sharpest annual moves came in 2022 and 2025: Operating Leases plunged 96.96% in 2022, then jumped 1853.1% in 2025.
- Assembly Biosciences' Operating Leases stood at $101000.0 in 2022, then surged by 1010.89% to $1.1 million in 2023, then surged by 134.22% to $2.6 million in 2024, then slipped by 21.65% to $2.1 million in 2025, then declined by 7.67% to $1.9 million in 2026.
- Business Quant data shows ASMB's Operating Leases at $1.9 million in Q1 2026, $2.1 million in Q4 2025, and $2.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Assembly Biosciences | 670.88 Mn | 350.52 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.74 Mn |
| Mar 31, 2026 | 1.90 Mn |
| Dec 31, 2025 | 2.06 Mn |
| Sep 30, 2025 | 2.21 Mn |
| Jun 30, 2025 | 2.35 Mn |
| Mar 31, 2025 | 2.49 Mn |
| Dec 31, 2024 | 2.63 Mn |
| Sep 30, 2024 | 113,000.00 |
| Jun 30, 2024 | 451,000.00 |
| Mar 31, 2024 | 791,000.00 |
| Dec 31, 2023 | 1.12 Mn |
| Sep 30, 2023 | 50,000.00 |
| Jun 30, 2023 | 64,000.00 |
| Mar 31, 2023 | 80,000.00 |
| Dec 31, 2022 | 101,000.00 |
| Sep 30, 2022 | 918,000.00 |
| Jun 30, 2022 | 1.77 Mn |
| Mar 31, 2022 | 2.50 Mn |
| Dec 31, 2021 | 3.33 Mn |
| Sep 30, 2021 | 4.14 Mn |